Use of SGLT2 inhibitors to treat diabetes has expanded greatly over recent years. Here David Morris looks at their possible side effects and how these might be managed
David Morris (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: